Study Title | A TACL Phase 1/2 Study of PO Ixazomib in combination with chemotherapy for childhood relapsed or refractory ALL and Lymphoblastic Lymphoma (Takeda) |
---|---|
Protocol ID | T2017-002 |
Disease (Sub Disease) | Leukaemia (ALL) |
Diagnosis Stage | Relapsed/ refractory |
Location | NSW / VIC |
Sponsor | Therapeutic Advances in Childhood Leukemia Consortium |
Collaborators | Takeda/ Children's Hospital Los Angeles |
Links | https://clinicaltrials.gov/ct2/show/NCT03817320 |
Trial Status | Open |
Trial Open Date | 12/02/2019 |
Sites | The Children's Hospital at Westmead / Sydney Children's Hospital / Royal Children's Hospital |
Study Type | Treatment |
Phase | Phase 1/2 |
Age Eligibility | 1 Year to 21 Years |
International registry ID's | NCT03817320 |